Immuneed was founded in 2014 and initially focused on the development of a novel immunotherapy for cancer. As the evaluation of this therapeutic vaccine grew more complex, we developed a proprietary platform to characterize the drug and predict outcomes in a clinical setting, thereby reducing animal studies and giving early indications of the effect in humans. In 2018, the vaccine project was acquired by the Norwegian pharmaceutical company Ultimovacs.
Today we are fully focused on developing Immuneed’s platform and associated services, which benefit biotech and pharmaceutical companies across Europe. Our platform, which is based on circulating, fresh human blood, is the only commercially available system that can monitor immune-mediated reactions in real-time – thereby linking preclinical data to clinical reality. By addressing important questions related to drug safety and immunology, we cut our customers’ costs and add value to drug development projects.
Our board of directors is responsible for corporate governance, overseeing risk and setting Immuneed’s strategy and policies, as well as monitoring our progress according to the annual business plan. The board represents the interests of our shareholders and is accountable for the proper conduct and growth of Immuneed’s business. Below you will find the board’s members, along with a short biography.